Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients

• Status: Completed
• Trial end date: 2020-01-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find a protein (ex. Polycystin 1 or mucin and cadherin like protein) in the urine that is changed after treatment of hydralazine.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Kansas Medical Center
• Treatments: Hydralazine

Criteria

Inclusion Criteria:

• Confirmed diagnosis of ADPKD

• estimated glomerular filtration rate (eGFR) > 60 ml/min/1.73m^2

Exclusion Criteria:

• History of systemic lupus erythematous or other rheumatologic disorder

• Baseline anti-nuclear antibody (ANA) >1:80 for females and >1:40 for males

• Blood pressure < 120/80 without anti-hypertensive

• Angina pectoris or myocardial infarction in the last 6 months

• Liver disease

• Allergy to hydralazine